We now provide proof of antileukemic efficacy in a patient with relapsed mutant-KIT D816V positive CBF AML – and point to an unexpected mode of action via release of the differentiation blockage and maturation of leukemia blasts. This evidence concerns the gene KIT and acute myeloid leukemia.